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前言  
 
本论文及其包含的工作是探讨癌症形成机理的基础研究。癌症已逐渐成为威胁人
类生存的头号杀手。那么为什么人会得癌症?  
 
人身体结构和功能的基本单位是细胞，一个成年人由约 60 万亿个细胞组成。在
人的一生中，大部分细胞都在严格的调控下进行分裂增殖，从而每天产生数百万
个新细胞来替代受损或老化的细胞。但是，在细胞分裂增殖这一过程中难免会有
错误发生。多数时候这些错误会被人体自身的免疫系统自动纠正、修复或者清
除。然而，少数没被纠正的错误则会不断累积，当这些错误累积到一定阶段，某
个携带错误信息的细胞则会发展成癌细胞，癌细胞进一步分裂出更多的子癌细
胞，从而形成癌症。癌细胞的共同特点是不受细胞外信号的调控，会无节制的生
长而不会死亡，同时逃脱免疫系统的监管，并且有能力转移到身体其他组织。 
 
癌症的发生并非一日之寒，它是长时间内因和外因作用下共同诱发的。人体内有
大约 20,500 个蛋白编码基因，其中两类和癌症形成发展息息相关的基因被称为
“原癌基因”和“抑癌基因”。在正常细胞中，原癌基因与抑癌基因共同维持细
胞的正常增殖活动。但这两类基因一旦发生编码错误，如突变、片段缺失和过多
复制等，就成为驱动癌细胞形成的内因。癌细胞形成的外因则包括各种外界刺
激，比如放射线、尼古丁、多环芳烃类化合物、病毒等。 
 
抑癌基因 p53，在细胞里调控着许多关键的信号通路。一旦细胞受到外界刺激，
p53 会被激活，触发细胞凋亡或细胞周期停滞等信号通路的开放，从而抑制细胞
的癌变。p53 突变则会导致其丧失对细胞的保护作用。目前已知的癌症中 p53 基
因的突变率高达 95%。在对 p53 所调控关键信号通路的研究让我们更清楚地了解
癌变的同时，这些信号通路中的重要因子也日益成为抗癌药物筛选和癌症治疗中
的关键靶点。 
 
本论文研究重点是 p53 转录调控的一个下游基因 Wig-1。Wig-1 是在 Klas Wiman
教授领导的实验组被首先发现并命名的。Wig-1 蛋白是对 mRNA 起调控作用的锌
指蛋白，它通过附着在 mRNA 的一段特殊的区域从而对 mRNA 进行调控。已经
被证实的 Wig-1 的作用对象有 p53、癌基因 Myc、调控细胞周期因子 p21 等。 
 
Paper I 研究证实了 Wig-1 的其他调控对象，包括促细胞凋亡基因 FAS 和调控细
胞周期因子 14-3-3σ 。paper II 发现了 Wig-1 蛋白在宫颈癌病人肿瘤样本中的表
达强度和宫颈癌病人生存率的相关性，揭示了 Wig-1 基因表达在宫颈癌诊断及预
后中起到的作用。Paper III 探讨了 Wig-1 在胚胎发育中的重要作用，发现 Wig-1
基因的敲除会导致小鼠胚胎期的死亡。Paper IV 进一步探索了 Wig-1 更多调控对
象在结构特征上的相似之处。 
 
此论文是本人四年多博士工作的成果，全部工作均是在卡罗琳斯卡医学院
(Karolinska Institutet) 肿瘤中心完成。卡罗琳斯卡医学院建立于 1810 年，位于瑞
典斯德哥尔摩，是全球高等教育中最大的一所医学大学。其中的诺贝尔委员会，
包括我的导师 Klas Wiman 在内，专门负责评审及颁发诺贝尔生理医学奖。 
ABSTRACT 
The tumor suppressor p53 is activated in response to a variety of stress conditions. Upon 
activation, p53 can trigger apoptosis or cell cycle arrest, or regulate metabolism and other 
cellular processes by transactivation of its targets genes. Wig-1 (also named ZMAT3) is a 
p53 target gene, and both Wig-1 mRNA and protein levels increase upon p53 activation. 
Wig-1 is a zinc finger protein that binds to double strand RNA. It is an AU-rich element 
(ARE) binding proteins (ARE-BPs) and acts as a regulator of mRNA stability via direct 
binding to AREs. The Wig-1 gene is localized to the long arm of chromosome 3(3q26), a 
region that is frequently amplified in cancer.  
 
In this thesis, I aimed to identify new Wig-1 mRNA targets and investigate the biological 
implications of the regulation of selected targets. I also explored Wig-1 protein 
expression in tumors as well as its clinical relevance, and determined the role of Wig-1 in 
mouse development.  
 
In paper I, we performed a microarray analysis of HCT116 colon cancer cells with or 
without Wig-1 knockdown and identified Wig-1 regulated mRNAs. We also discovered 
that Wig-1 promotes cell cycle arrest rather than cell death upon cellular stress through 
regulation of p53 targets FAS and 14-3-3σ. Wig-1 regulates FAS mRNA negatively 
through binding to 3’UTR AREs in FAS mRNA.   
 
In paper II, we studied Wig-1 expression in cervical carcinoma samples and found that 
the Wig-1 protein expression pattern in tumors is associated with patient survival. 
Patients with moderate nuclear Wig-1 staining and positive cytoplasmic Wig-1 staining 
in their tumors show better survival than patients with high nuclear Wig-1 staining and 
negative cytoplasmic Wig-1 staining.  
 
In paper III, we showed that Wig-1 null mice embryos die before the blastocyst stage. We 
also found that Wig-1 knockdown in mouse embryonic stem cells (mESCs) leads to a 
reduction in proliferation rate. Wig-1 binds to and regulates both c-Myc and N-Myc 
mRNA in mESCs. Since Myc has essential roles during embryonic development, we 
suggest that deficient regulation of Myc in absence of Wig-1 may explain the observed 
embryonic lethality.   
 
In paper IV, we performed RNA-immunoprecipitation (RIP) followed by high-
throughput RNA sequencing in HCT116 and Saos2 cells. We identified Wig-1 bound 
mRNAs and found a significant enrichment of mRNAs with AREs in their 3’UTRs as 
compared to unbound mRNAs.   
 
In summary, this thesis greatly expands theWig-1 targets repertoire and further explores 
the role of Wig-1 as a survival factor in cell growth and early embryonic development. 
Our findings also suggest that Wig-1 may serve as a molecular biomarker together with 
other conventional clinical markers for cervical cancer prognosis. 
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1 THESIS SUMMARY  
1.1 INTRODUCTION 
1.1.1 Cancer 
Cancer is responsible for one in seven deaths worldwide1. Cancer develops as a result of 
deficient control of cell growth and cell survival. At later stages, tumors may gain the 
ability to invade other tissues and form distant metastases. Cancer can arise in almost any 
tissue in the human body and is classified according to the cell type in which is originates 
(Figure 1).  
 
Sarcorma'''begins'in'
the'connec,ve'or'
suppor,ve',ssues'such'
as'bone,'car,lage,'fat,'
muscle,'or'blood'vessels
Brain+and+spinal+cord+
tumors+'''central'
nervous'system'cancer+
Muscle'ﬁbre'cells'
Bone'cells
An'astrocyte'

Carcinoma,+formed'by'
“epithelial'cells”,'from'
inside'or'outside'
surfaces'of'the'body
Lymphoma+and+
myeloma,+begins'in'the'
cells'of'the'immune'
system'
Squamous'cells'
White'blood'cells
lymphocyte
Adenomatous'cells
Leukaemia,+cancer'of''
blood'cells''

 
Figure 1. Five major cancer types.  (main source: http://www.cancerresearchuk.org. Photo of the 
three Graces marble statue was taken in the Louvre Museum in Paris.  
 
All of these different types of cancer share 10 common features defined by Hanahan and 
Weinberg as the Hallmarks of cancer. (1) Cancer cells divide in an uncontrolled manner -
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- ”sustain proliferation by their own”; (2) they are “blind” and “deaf”, as they ignore 
commands from the extracellular environment; (3) they resist cell death and evade 
growth suppressions; (4) they stimulate the growth of blood vessels to get nutrients; (5) 
they are “greedy”-- since they ignore cellular contact inhibition and become invasive and 
able to metastasize; (6) they are immortalized with unlimited replicative potential; (7) 
they alter the normal energy metabolism; (8) they are genomically instable and have 
accelerated mutation rates; (9) they avoid immune destruction; (10) they induce 
inflammatory responses, thus supplying bioactive molecules that facilitate the other 
hallmarks 2,3. 
 
Underlying these Hallmarks are genomic alterations, such as mutations, deletions and 
amplifications, in two major groups of genes: proto-oncogenes and tumor suppressor 
genes4–7. Alterations in proto-oncogenes convert them into oncogenes and drive 
uncontrolled cell proliferation. For example, the c-Myc oncogene is activated by 
chromosomal translocation in Burkitt lymphoma8,9, and the N-Myc oncogene is 
amplified in for instance neuroblastoma 10,11. Alterations in tumor suppressor genes, on 
the other hand, abolish their tumor suppressor function. For example, the tumor 
suppressor gene TP53 is the most frequently mutated gene in cancer5. Mutant p53 has 
lost its ability to induce cell cycle arrest or cell death by apoptosis, and/or regulate 
metabolism and other cellular processes upon DNA damage or oncogenic stress. This 
allows tumor growth.  For this reason, the p53 protein has been named the “guardian of 
the genome” 12. 
 
1.1.2 The p53 tumor suppressor 
1.1.2.1 Discovery of p53  
Since its discovered in 197913,14, the p53 has been the focus of intense research 
worldwide. The mutation frequency of p53 in cancer ranges from 2% to 95% depending 
on the cancer type5 (www.cbioportal.org). Inherited germline p53 mutations are the 
underlying genetic defect in the Li-Fraumeni syndrome, a familial syndrome comprising 
multiple cancers such as osteosarcomas, breast cancer, soft tissue sarcoma and 
leukemia15,16, developing  at an early age. Moreover, p53 can acquire “gain-of-function 
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mutations”, that is, mutations that confer new or enhanced activity, promoting tumor 
proliferation rather than inhibiting cell growth17,18. The tumor suppressive function of p53 
is also supported by studies in mice19,20. Complete lack of p53 in mice leads to 
spontaneous development of a variety of neoplasms by 6 months of age and death before 
9 months of age19. 
 
1.1.2.2 p53 and cell fate decision 
The p53 protein is a key transcriptional factor that is activated in response to cellular 
stress, including DNA damage, oxidative stress or oncogenic stress, thus inducing many 
critical cellular functions (reviewed in21–23). It has been suggested that low levels of stress 
induce p53-mediated cell cycle arrest, DNA repair, stem cell maintenance, and 
antioxidant response and regulates fertility, metabolism, while high stress levels trigger 
apoptosis, senescence, stem cell erosion and/or pro-oxidant activity (24,reviewed in22,25–28). 
This is summarized in Figure 2.  
 
Figure 2. Schematic representation of p53 responses upon different stress levels, and its 
respective regulated pathways.  
A growing list of genes that are transactivated by p53 have been identified and their 
contributions to different p53 regulated pathways is well established in many cases. For 
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example, p53 induces cell cycle arrest mainly through its targets p21 (other names 
WAF1/CIP1/CDKN1A)29 and 14-3-3σ30, and triggers apoptosis through pro-apoptotic 
genes such as PUMA31, NOXA32 and FAS33. p21 is also known to be a key regulator in 
senescence34,35.  
If the task of researches in biology is to reduce the complicated to the simple and 
illustrate the beauty of simplicity in nature, the study of p53 has made this task a lot 
more challenging. Although p53-mediated cell-cycle arrest, senescence, and apoptosis 
are believed to be prime barriers against tumor growth, emerging evidence suggests that 
this is not the full picture. Li et al has shown that while p533KR/3KR cells carrying the 
p53 acetylation mutant K117R/K161R/K162R which fails to activate p21 and PUMA 
and cannot enter cell cycle arrest, apoptosis and senescence; mice with the p533KR/3KR 
mutation do not develop early onset of thymic lymphomas36. In another study by 
Valente et al., thymocytes derived from p21-/- Puma-/- Noxa-/- triple knockout mice 
were unable to undergo p53-mediated cell cycle arrest, apoptosis, and senescence. 
Nevertheless, unlike p53-/- mice, none of these mice developed a tumor (or other 
diseases) within the 500 days observation period37. 
 
The above findings suggest that p53-induced cell cycle arrest, senescence and apoptosis 
are dispensable for p53-mediated tumor suppression and raise the possibility that other 
“unconventional” p53-mediated cellular processes, e.g. metabolism38 and DNA damage 
repair37, may be more critical to the tumor suppressor or activity of p53. Preliminary 
data have suggested that Wig-1 is a key mediator of p53's tumor suppressor function. 
An shRNA library screen led to the identification of Wig-1 as a candidate gene whose 
inactivation induces lymphomas in 50% of mice transplanted with p21-/- Puma-/- 
double knock out hematopoietic stem/progenitor cells (HSPCs) within 350 days (A. 
Strasser, Melbourne, personal communication).  
 
1.1.3 The Wig-1 gene and protein  
WIG-1 (WT p53-induced gene 1, also known as ZMAT3 or PAG608) is a p53 target gene 
that has previously been identified in our lab39. By using a PCR-based differential display 
technique, two WIG-1 transcripts were found to be upregulated by wtp53 expressed as a 
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temperature-sensitive mutant p53 in mouse T lymphoma cells39. WIG-1 (PAG608) was 
characterized independently in rat by another research group at almost the same time40.  
 
The human WIG-1 was identified subsequently and localized to 3q26.3241. Due to 
alternative splice site usage, human Wig-1 is expressed as two main transcript variants 
corresponding to two isoforms with 288 and 289 amino acids residues, respectively. On 
the other hand, mouse Wig-1 is expressed as one isoform containing 290 amino acids.  
 
The Wig-1 protein contains three widely spaced zinc finger (ZF) motifs of the Cys2-His2 
type (residues 72-94, 149-171 and 247-269) and a nuclear localization signal (residues 
194-210). The Wig-1 zinc fingers are special in two aspects: (1) the inter-histidine 
distance within the zinc fingers are five amino acids compared to the usual three to four 
amino acids; (2) the long linkers between the zinc fingers are 56-75 amino acids instead 
of six to eight as in most other zinc finger proteins. The first two ZFs show strong 
homology to each other while the third ZF motif does not, except that the cysteins and 
histidines are conserved. The Wig-1 proteins are highly conserved at the protein level 
with 100% amino acid sequence identity between human and primates such as 
chimpanzee, gorilla, orangutan and gibbon, and 87% amino acid identity between human 
and mouse Wig-1. Moreover, the ZFs are almost completely conserved all the way from 
amoeba to human Wig-1 42  (Figure 3). 
 
CZF1 ""NLS"N ZF2 ZF3 
1 72" 94" 149" 171" 194" 210" 247" 269" 288"
 
MILLQHAVLPPPKQPSPSPPMSVATRSTGTLQLPPQKPFGQEASLPLAGEEELSKGGEQD
CALEELCKPLYCKLCNVTLNSAQQAQAHYQGKNHGKKLRNYYAANSCPPPARMSNVV
EPAATPVVPVPPQMGSFKPGGRVILATENDYCKLCDASFSSPAVAQAHYQGKNHAKRL
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LAMCVTPSGQFYCSMCNVGAGEEMEFRQHLESKQHKSKVSEQRYRNEMENLGYV 
 
Figure 3.  Human Wig-1 protein structure and its sequence (three zinc fingers and NLS are 
highlighted in the sequence). 
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Human Wig-1 is expressed as two proteins, one full-length Wig-1 species and one that 
lacks the 20 N-terminal amino acid residues, due to translation initiation from different 
ATGs. The full-length protein is initiated from the main ATG residing in a relatively 
weak context, while the smaller protein is initiated from a downstream in-frame ATG. 
Translation initiation at the downstream ATG is explained by the existence of an out of 
frame ATG situated 19bp upstream of the main ATG and a short open reading frame. 
The two Wig-1 species are visualized by Western blotting using a rabbit polyclonal 
antibody raised against the full-length protein43 and another rabbit polyclonal antibody 
against the C-terminus.  
 
The unusual zinc finger structure of Wig-1 is shared by a small group of double-stranded 
RNA (dsRNA) binding proteins44, with Jaz as the most well known protein45. Indeed, we 
have found that Wig-1 binds to both long and short dsRNA46. The first and second zinc 
fingers are critical for binding.  
 
The crystal structure of Wig-1 has not been determined, but ModBase47, a database of 
comparative protein structure models, provides a predicted 3D structure model for a 
fragment of the Wig-1 protein (https://modbase.compbio.ucsf.edu). 
 
1.1.4 Wig-1 is an AU-rich element binding protein 
1.1.4.1 What is an AU-rich element? 
Adenylate-uridylate-rich elements (AREs) within 3’ untranslated regions (3’UTR) are 
signals for rapid degradation of mRNAs48,49. AREs are one of the most prevalent cis-
acting elements site in 3’UTRs48,50,51 that can interact with AU-rich element binding 
proteins (ARE-BPs). Approximately 17% of human mRNAs are estimated to contain 
one or several AREs motifs as reported by AREsite, a database for investigating AREs 
in vertebrate52. AREs containing mRNAs are a functionally diverse group of proteins 
including many oncoproteins (e.g. c-Fos53, c-Myc54) and cytokines (e.g. tumor necrosis 
factor TNF-α55, interleukin 656). Most of them play essential roles in cell proliferation, 
differentiation and in the immune response (reviewed in57). 
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1.1.4.2 What is an AU-rich element binding protein? 
ARE-BPs are proteins that bind to AREs and have roles in controlling 
posttranscriptional gene expression 58,59. AREs in different mRNAs can be bound by 
more than one protein under different conditions, and one ARE-BP can bind to more 
than one ARE-containing mRNA.  More than 20 ARE-BPs have been identified so far 
and they can be divided into three distinct groups (reviewed in Barreau et al. 2005): (1) 
mRNA destabilizing proteins, such as tristetraprolin (TTP) 60,61, butyrate-regulated 
factor-1 (BRF1/ZFP36L1)61,62, and KH domain-splicing regulatory protein (KSRP)63,64; 
(2) mRNA-stabilizing proteins, such as embryonic lethal abnormal vision (ELAV)-like 
protein 1 (also named HuR)65; and (3) proteins promoting both mRNA degradation and 
stability such as ARE binding factor-1 (AUF1/hnRNP D)66,67.  
 
Most ARE-BPs cause destruction of their binding mRNAs through an ARE-dependent 
decay by recruiting the degradation machinery 68,69. In addition, they can also regulate 
mRNA translation 57,70. These two post-transcriptional regulation mechanisms of ARE-
BPs will be discussed in the following sections. 
 
 Additionally, ARE-BPs are also involved in regulating mRNA localization, mRNA 
trafficking, miRNA maturation and several other aspects of RNA biology (reviewd 
in71 ).  
 
As discussed above, ARE-containing mRNA are mostly oncogene and inflammatory 
mediators, and therefore it is not surprising that changes of ARE-BPs expression levels 
are associated with tumor growth72–74. ARE-BPs are also involved in promoting 
angiogenesis75,76 and metastasis77, both known hallmarks of cancer, indicating that 
ARE-BP expression levels may be useful prognostic and predictive markers in cancers 
and that ARE-BPs could also be potential targets for cancer treatment78. 
 
Furthermore, ARE-BPs have essential roles in stem cell proliferation and 
embryogenesis79–81. Brf1-deficient mutants mice develop abnormal placenta and die 
during the midgestation stage79. HuR null embryos show defects in limb, skeletal and 
spleen development and fail to survive beyond midgestation. This lethality is due to 
deregulation of several HuR target mRNAs81. These findings suggest that ARE-
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containing mRNAs and their binding proteins are subject to fine-tuned regulation during 
development.  
 
1.1.4.3 ARE-mediated decay (AMD) and ARE-BPs 
ARE-mediated decay (AMD) promotes mRNA degradation mainly through two 
different mechanisms: exonuclease-mediated decay and endonuclease-mediated 
decay82,83 (Figure 4). Exonuclease mediated decay begins with shortening of the poly(A) 
tail (deadenylation). This is mediated mainly through three groups of enzymes:  (1) 
cytoplasmic deadenylase complexes which are poly(A)-binding protein (PAB)-specific 
ribonuclease 2 (PAN2) and PAN384; (2) CCR4–NOT transcription complex subunit 6 
(CNOT6), CNOT6L, CNOT7 and/or CNOT885; and (3) the deadenylase poly(A) 
ribonuclease (PARN). It is then followed by removal of the 5’ cap (decapping) through 
the Nudix domain proteins mRNA-decapping enzyme 2 (DCP2) or NUDT16 86. Then 
degradation of the mRNA body proceeds from both ends, with 5’-to-3’ degradation by 
5’-to-3’ exoribonuclease 1 (XRN1)  and/or 3’-to-5’ degradation by exosomes (Figure 
4A).  
 
The endonuclease-mediated AMD is, on the other hand, initiated by endonuclease 
cleavage within the body of the mRNA, followed by degradation of the upstream 
cleavage product by the exosome and degradation of the downstream cleavage product 
by XRN187 (Figure 4B). Another group of endoribonucleases is represented by 
Argonaute (AGO), a component of the RNA-induced silencing complex (RISC). 
Association between AGO and miRNA, short RNA molecules (20-22nts) involved in 
post-transcriptional regulation of mRNA88 has shown to mediate the AMD effect89. 
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Figure 4. ARE-mediated decay (AMD) mechanisms. A. exonuclease decay pathway. B. 
endonuclease decay pathway.  
 
ARE-BPs mainly exert the destabilizing effects on target mRNAs by recruiting these 
deadenylases or endoribonucleases to the mRNA, or stabilizing the mRNA through 
interference with each individual step of AMD90,91. miRNA can bind to ARE-BPs and 
enhance or inhibit the regulation functions of ARE-BPs92–95. 
 
1.1.4.4 Translational regulation by AREs and ARE-BPs 
A contribution of ARE-BPs to mRNA translation control has also been reported. The 
ARE-BP named T-cell intracellular antigen 1 (TIA-1) has a translational repressive effect 
on the cytokine TNF-α 96 and the enzyme cyclooxygenase-2 (COX-2)97. HuR, for 
example, was also reported to act as both a positive and a negative translational regulator. 
Elevated HuR expression greatly enhanced translation of p53 mRNA with no effect on 
p53 mRNA abundance98,99, while on the other hand, overexpression of HuR inhibited 
polysome recruitment of TNF-α and COX-2100.  
 
However, the exact mechanism for this translational regulation by ARE-BPs is not well 
understood. One possibility is that ARE-BPs regulate translation through recruitment of 
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ribosomes. This is supported by studies showing that the RNA-binding protein fragile-X- 
mental-retardation-related protein 1 (FXR1) interacts with AGO2, which then associated 
with an ARE in TNF-α mRNA. This complex is then recruited by FXR1 to ribosomes, 
thereby upregulating TNF-α mRNA translation70. A possible alternative mechanism 
involves stress granules (SGs), a type of cytoplasmic granule that can be induced upon 
stress101. ARE-BPs can recruit their target mRNAs to stress granules in response to a 
variety of stresses in an ARE-dependent manner102,103. mRNAs in SGs are subjected to 
storage, stabilization or decay largely depending on the duration and severity of the 
stress104. Once the stress is gone, SGs dissemble and release mRNA and its associated 
ARE-BPs that any then be available for translation reinitiation103,105.  
 
1.1.4.5 Wig-1 function  
Previous studies have shown that Wig-1 is amplified and overexpressed in squamous cell 
carcinoma of the lung106. Ectopic overexpression of Wig-1 was shown to inhibit cell 
growth41. Additionally, overexpression PAG608, the rat homolog of Wig-1, promotes 
cell apoptosis40. Interestingly, both overexpression of exogenous Wig-1 and knockdown 
of endogenous Wig-1 can inhibit cell growth107. These studies indicate that Wig-1 levels 
are tightly regulated in the cell and that a well-balanced expression of Wig-1 is necessary 
for cell normal growth.  
Wig-1 knockdown in mouse liver and brain by using antisense oligonucleotides caused 
changes in expression of several genes, a number of which were shown to be relevant 
for both nervous system function and cancer progression108.  
 
Our lab has demonstrated that Wig-1 is an ARE-BP that acts as a regulator of mRNA 
stability through direct binding to AREs in the 3’UTR of its target mRNAs. Wig-1 
stabilizes p53 mRNA by binding to an ARE in the p53 3’UTR and preventing mRNA 
deadenylation109. By doing this, Wig-1 enhances p53 protein expression levels and 
potentiates the p53 stress response. Wig-1 was also shown to bind to a stem loop 
structure on the 3’ UTR of the p53 target p21 mRNA and to recruit the miRNA-
associated RISC complex to its target site, thereby promoting to miRNA-mediated p21 
decay, which resulted in premature senescence110.  
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1.1.5 Regulation of Wig-1 
1.1.5.1 Transcriptional regulation 
How is Wig-1 regulated? Both Wig-1 mRNA and protein are induced by DNA damaging 
agents such as gamma radiation and cisplatin in a p53 dependent manner39,40. Wig-1 is a 
bona fide p53 target gene as confirmed by several studies111–113. The mouse WIG-1 
promoter contains three putative p53-binding motifs. Two of them form a strong complex 
with p53 and contribute significantly to p53-dependent transactivation as demonstrated 
by electrophoretic mobility shift assays114. Human WIG-1, on the other hand, has a 
perfect consensus p53 response element in intron 1 (F. Hellborg et al., unpublished data).  
 
Yet we have found that Wig-1 is expressed also in cells lacking p53, indicating that p53 
is not the only transcriptional factor that regulates Wig-1 expression. Indeed, by using 
CSCAN115, a web resource that includes a large collection of genome-wide ChIP-Seq 
experiments, we have identified a number of novel transcriptional factor (TFs) that could 
regulate Wig-1 expression in different cell lines (Table 1). This suggests that Wig-1 is 
regulated by different TFs under different conditions.  
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Table 1. List of transcriptional factors binding to either human or mouse WIG-1 promoters  
(source: CSCAN) 
 
ATF2 GM12878 BHLHE40 CH12
CCNT2 K562 CHD2 CH12
CDP GM12878 COREST CH12
CEBPB H1,hESC ETS1 CH12
E2F1 Hela,S3 HCFC1 MEL
E2F4 K562 IRF4 NFS,201
E2F6 H1,hESC,Hela,S3,K562 JunD CH12
ELF1 K562,MCF,7,HeG2 Mix1 MEL
ELK1 K562 MyoD C2C12
ELK4 Hela,S3 Myogenin C2C12
ETS1 K562 TAL1 Megakaryo
ELK4 Hela,S3 UBF CH12
EgrB1 K562,GM12878 USF2 CH12
FOXM1 GM12878 ZNFBMIZDBCP1 CH12
GABP A549,GM12878,Hela,S3,HepG2,BK562,MCF,7,BSK,N,SH cBJun CH12
HABE2F1 Hela,S3,MCF,7 cBMyc CH12
HDAC2 MCF,7 p300 CH12
HMGN3 k562 Med1 MEF
IRF4 GM12878
MTA3 GM12878
MAX HCT116,BNB4
Mxi1 Hela,S3
NFIC HepG2
NFKB GM12892,BGM15510,BGM18951,GM19099,GM19193
Nrf1 GM12878,H1,hESC,Hela,S3,BHepG2,BK562,BSK,N,SH
PAX5BC20 GM12878
PML GM12878
PU.1 GM12878,GM12891,HL,60,BK562
Pbx3 GM12878
Rad21 IMP90
STAT5A GM12878
Sin3AkB20 A549,BGM12878,BH1,hESC,BHepG2,BK562
TAF1 GM12891,GM12892,K562,BSK,N,SH
TBP K562
TCF7L2 GM12878,HCT116,BPANC,1
THAP1 K562
USFB1 ECC,1
YY1 ECC,1,SK,N,SH
ZC3H11A K562
cBFos MCF10A
cBMyc MCF,7
TF TFHumanBcellBlines MouseBcellBlines
 
 
A549: human lung adenocarcinoma epithelial cell line; C2C12: myoblast cell line derived from 
thigh muscle of C3H mice after crush injury; CH12: mouse B-cell lymphoma; ECC1: 
endometrium adenocarcinoma; GM(#): epstein-Barr Virus transformed B-lymphocyte, 
lymphoblastoid; H1-hESC: human embryonic stem cell; Hela-S3: cervical carcinoma; HepG2: 
hepatocellular carcinoma; HCT116: colorectal carcinoma; K562: myelogenous leukemia; HL-
60: human promyelocytic leukemia cells; IMP90: the human diploid fibroblast strain; MCF7: 
mammary glad, adenocarcinoma; MCF10A: mammary gland, non-tumorigenic epithelial, 
inducible cell line; MEF: mouse embryonic fibroblast; MEL: mouse erythroleukemia; NB4: 
acute promyelocytic leukemia cell line; NFS-201: mouse B cell lymphoma; Megakaryo: 
megakaryocyte (primary cells); PANC-1: pancreas epithelioid carcinoma; SK-N-SH: 
neuroblastoma cell line differentiated with retinoid acid. 
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1.1.5.2 Post-translational regulation 
Protein post-translational modifications (PTMs) comprise mainly phosphorylation, 
acetylation, oxidation, methylation, ubiquitylation and sumoylation116. PTMs can be 
either reversible or irreversible and often serve as on and off switches or modulators of 
protein activity and targeting. PTMs also regulate the assembly and disassembly of 
protein–protein and protein–nucleic-acid interactions117. Among them, protein 
phosphorylation that usually occurs on serine, threonine and tyrosine residues is the most 
common type of PTM118. Phosphorylation at different sites on ARE-BPs have been 
shown to control their subcellular distribution or affect their binding affinity119–124.  
 
We identified Wig-1 PTMs by immunoprecipitation of Flag-Wig-1 protein in cisplatin 
treated Saos-2 cells followed by mass spectrometry (MS). A number of PTMs of Wig-1, 
including phosphorylation, acetylation and methylation were identified. Interestingly, 
Wig-1 PTM changed upon treatment with cisplatin, suggesting that Wig-1 might have 
different activities and regulate different targets in non-stressed cells as compared to 
stressed cells.  
 
1.1.6 Wig-1 and cervical carcinoma 
1.1.6.1 Wig-1 alterations in cancer  
Human WIG-1 is localized to chromosome 3q26.3241, a region that contains several genes 
with relevance to cancer. Gain of 3q region with a minimal common region at 3q26.1-27 
has been reported in lymphoma125, squamous lung carcinoma126,127 and other cancer 
types128. Online databases show that WIG-1 is commonly deregulated, amplified or 
mutated in cancer. Analysis of the in silico transcriptomics database (IST) and the gene 
expression Atlas shows that WIG-1 is amplified in various tumor types including AML, 
glioma and lung cancer (http://ist.medisapiens.com/, www.ebi.ac.uk/gxa). According to 
cBioPorta that with exploration and analysis of the Cancer Genomic Atlas (TCGA) data, 
WIG-1 is commonly amplified in many tumors, including 54 % of lung squamous cell 
carcinomas, 28% of ovarian cancer, 24% of breast cancer, 21% head& neck cancer, 18% 
of Esophagus cancer and 18% cervical carcinomas (www.cbioportal.org).  
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1.1.6.2 Cervical carcinoma  
Cervical carcinoma arises from the uterine cervix and ranks as the third most common 
type of cances in women worldwide (following breast and colorectal cancer)129. National 
estimates of 5-year survival of cervical cancer range from less than 50% to more than 
70%, according to the global surveillance of cancer survival study130. Although the 
incidence and mortality rates of cervical carcinoma have dropped substantially in 
developed countries after the high-coverage screening131–134, this disease remains a 
serious health threat in places with poor health care such as Eastern Africa, South-Central 
Asia and Melanesia135.  
Two major types are squamous cell carcinoma (SCC), accounting for around 80% of the 
cases, and adenocarcinoma (ADCA) that accounts for the remaining 20%136. SCC 
derived from the flat, skin-like epithelial cells that cover the outer surface of the cervix 
(the ectocervix) while the ADCA is derived from glandular cells on the body of the 
uterus (the endocervix). Both types of cancer share the same major risk factor, namely 
infection with high-risk (HR) human papillomavirus (HPV)137, with HPV 16 and HPV 18 
as the two predominant types135,138.  
 
Most HPV infections are cleared within two years139, but with persistent infections, a low 
grade lesion can progress to pre-cancer and further invasive cancer135. HPVs affect two 
major cellular tumor suppressor pathways by encoding two early proteins, E6 and E7. E6 
interacts with p53 tumor suppressor and targets it for degradation, disrupting p53-
dependent apoptosis and/or senescence pathways140,141. E7 binds to and blocks another 
tumor suppressor, the retinoblastoma protein (pRB), thereby interfering with G1/S 
transition control in the cell cycle142,143. Consequently, HPV infection may lead to 
malignant transformation. Therefore, the screening with test for HPV DNA is the most 
effective way to detect early stage infection and to prevent the progression of invasive 
cervical cancer144,145. 
 
This is not the end of story for curing cervical cancer patients. HPV-negative cervical 
carcinoma is associated with different risk factors146 and has a poor prognosis compared 
to HPV-positive cervical carcinoma147–149. Increased mortality in HPV-negative patients 
might be due to mutation of important tumor suppressor genes such as p53 and RB, but 
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studies have shown that there is no clear correlation between p53 mutation and 
development of HPV-negative cervical carcinoma, indicating that additional mechanisms, 
as yet unidentified, might be involved150.   
 
1.1.6.3 Wig-1 expression in cervical carcinoma  
Genomic alterations such as gene amplifications are key features of cervical 
carcinogenesis151. Gain of copy number of the long arm of chromosome 3 serves as a 
biomarker for progression from cancer in situ (CIN) to invasive carcinoma152. Genes 
localized to the 3q26 region, including the phosphoinositide-3-kinase catalytic alpha 
polypeptide gene (PIK3CA)151 and the telomerase RNA component gene (TERC) 153,154. 
However, no previous study has been carried out to investigate whether WIG-1 gene, 
which is also localized this region, contributes to cervical carcinogenesis. Analysis of 
TCGA data revealed that WIG-1 is amplified in 35 cases (18%) of the total 191 cervical 
squamous cell carcinoma and endocervical adenocarcinoma cases that were studied.  
 
1.1.7 Wig-1 and stem cells  
1.1.7.1 The early embryonic development  
Mammalian embryogenesis initiates with the fertilization of an egg cell (oocyte) by a 
sperm cell. Once fertilized, the cell containing two sets of chromosomes (diploid) is 
called a zygote. The zygote undergoes several divisions to form 2 cells and then 4 cells, 
followed by 8 cells, 16-32 cells (also called morula because of the mulberry shape), 64 
cells and then 128 cells. At the 64 and 128-cell stages, this cluster of cells is also called 
blastocyst, from a greek word meaning “a sprout”. The blastocyst comprises an inner cell 
mass (ICM) that will grow into an embryo and the outer layer called trophectoderm, 
which will form the placenta and initiate the implantation in the uterus155. Cells derived 
from the inner cell mass are pluripotent and are called embryonic stem cells156,157. They 
are widely used in scientific research and has also been applied in clinical trial158.  
 
The formation of the blastocyst before implantation is called the early embryonic 
development stage. In the mouse, it takes about 3-4 days and in human 5 days (Figure 5). 
The gene regulation at this early embryonic stage can be separated into two phases: 
maternal control and zygotic control. Maternal control means that maternal RNAs 
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existing in the egg are being used to drive early development. These RNAs are degraded 
gradually during embryogenesis159. Zygotic control means that zygotic transcripts are 
expressed and drive embryonic development from the 2-cell stage in the mouse160–162 and 
from the 4 to 8-cell stages of human development163. 
 
 
 
Figure 5. The early embryonic development stages (figure by Sophia Ceder, link: 
www.ceder.graphics)  
 
1.1.7.2 Wig-1 expression during early embryogenesis 
`Wig-1 maternal mRNA expression is already detectable at the mid-2 cell stage after 
fertilization but drops at the late-2 cell stage. At that time, zygotic transcription kicks in, 
leading to a rapidly elevated Wig-1 mRNA expression at the 4 cell stage and a peak at 8 
cell stage, followed by stable expression levels until the late blastocyst stage164. 
 
1.1.7.3 Wig-1 expression in stem cells 
Wig-1 was found to be upregulated in stem cells including haematopoietic, neuronal and 
ESCs as compared to their corresponding differentiated cell types165. Another study 
showed increased Wig-1 expression in bone marrow cells lacking the proto-oncogene 
Bmi1, a polycomb group repressor, which is essential for haematopoietic stem cell 
(HSCs) self-renewal166. An shRNA screen to find novel ESC regulators showed that 
Wig-1 silencing by shRNA results in reduced hESCs identity167. The role for Wig-1 in 
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ESC maintenance is supported by the observation that Wig-1 mRNA expression levels 
are gradually decreased as mESCs undergo differentiation168. Furthermore, Wig-1 was 
also shown to be one of the novel RNA-binding proteins in the mESC mRNA 
interactome169.   
 
All of there above suggests that Wig-1 may be important for the maintenance of ESCs 
and embryonic development.  
 
1.1.8 The Myc oncogene 
Myc was originally identified as a viral oncogene, v-Myc, in MC29, a virus that induces 
myelocytomatosis and other neoplastic diseases in chickens170,171. c-Myc, the cellular 
homolog of v-Myc and the founding member of the Myc family, was characterized172 and 
found to be frequently rearranged and overexpressed in Burkitt lymphoma and murine 
plasmacytoma8,9. The other two family members, MYCN173,174 and MYCL175, were later 
identified as amplified oncogenes in neuroblastoma and lung cancer.  
 
Indeed, about 50% of human cancers show gene amplification and/or overexpression of 
MYC/Myc176 (www.cbioportal.org). c-Myc/N-Myc/L-Myc have distinct expression 
patterns in adult tissues177. Overexpression of c-Myc is common in both blood-borne and 
solid tumors. N-Myc is most often overexpressed in cancers of neural origin, such as 
glioma and neuroblastoma178, while MYCL gene amplification is frequently observed in 
small cell lung cancer175.  
 
1.1.8.1 Role of Myc as transcription factor   
The Myc family proteins are basic-helix-loop-helix leucine-zipper (bHLH-LZ) 
transcriptional factors in which the bHLH functions as DNA-binding domain while the 
LZ forms a heterodimers with another bHLH-LZ protein named Max179. In most cases, 
Myc-Max heterodimers bind directly to the E-box sequence  (CACGTG) of the target 
genes. Myc-Max regulates a wide range of genes, participating in genomic stability, cell 
cycle progression, apoptosis, differentiation and metabolism (reviewed in180–182). In 
addition, Myc can also indirectly regulate mRNAs stability via ARE-BPs. Myc represses 
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transcription of TTP, one of the ARE-BPs that participate in the degradation of ARE-
containing mRNAs183.  
 
1.1.8.2 Myc role in stem cell and embryonic development 
All three Myc family members are abundantly expressed throughout embryonic 
development184, and targeted deletion of c-Myc or N-Myc in mice causes embryonic 
lethality 185–191 while silencing of L-Myc leads to no detectable phenotype192. c-
Myc knockout mice die before E10.5 with hematopoietic and vascular defects189. The 
dose of N-Myc is important for the severity of the phenotype of N-Myc knock out 
embryos (reviewed in 193). N-Myc null mutations result in embryonic lethality at E11.5, 
with defects in heart, liver, stomach, lung, kidney, and nervous systems 
development186,188,191. On the other hand, N-Myc hypomorphic mutants and a compound 
heterozygous genotype which still show approximately 15% expression levels of N-Myc 
protein, result in a significantly longer survival time of the embryos and more-restricted 
effects on organs such as lung and heart187,190,194 compared to N-Myc null knockouts.   
 
The observation that c-Myc or N-Myc deficient mouse embryos survive until 
midgestation (E9-E11) can be explained by the fact Myc gene family expression patterns 
become most divergent at that time. Indeed, knockout of their common obligate partner 
Max is embryonic lethal at an earlier embryonic stage E6.5195. Additionally, it has been 
shown that N-Myc can rescue the essential role of c-Myc in mouse embryonic 
development, cellular survival and differentiation 196.  
 
c-Myc is also crucial for maintenance of embryonic stem cell (ESC) pluripotency. It 
sustains stem cells self renewal by blocking differentiation independent of LIF 
expression197. Later on, c-Myc was identified as one of “magic four” genes for 
reprogramming fibroblasts into induced pluripotent stem cells (iPS) 198–201.   
 
Double knockout of N-Myc and c-Myc in ESC causes growth inhibition due to cell cycle 
arrest and an increase in apoptosis as well as differentiation into ectoderm, mesoderm, 
and endoderm derivatives. Chimeric embryos injected with double knock out mESCs 
mostly failed to develop and or in same rare cases when they did form, they had very 
severe defects202.  
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Taking all this together, both c-Myc and N-Myc are key regulators of embryogenesis and 
variations in Myc expression levels have important consequences. Myc also plays crucial 
roles in the maintenance of pluripotency and self-renewal capacity of stem cells. 
 
1.1.8.3 Regulation of Myc by Wig-1 
Both N-Myc and c-Myc can be regulated by ARE-BPs203,204 or co-regulated by ARE-BPs 
and microRNAs205.  HuR, a well studied ARE-BP, reduces c-Myc expression by 
recruiting miRNA let-7-associated RISC to the 3'UTR of c-Myc mRNA205. Two other 
ARE-BPs: AUF1 and TIAR affect c-Myc mRNA translation through an ARE and this 
regulation is a dynamic process dependent on the ratio of AUF1 and TIAR bound to c-
Myc mRNA206. 
 
In conclusion, it is perhaps not surprising that N-Myc is also regulated by Wig-1 since we 
had identified Wig-1 as an ARE-BP.  Wig-1 stabilizes N-Myc mRNA via binding to its 
proximal ARE in the 3’UTR, thereby promoting N-Myc-driven tumor growth. Silencing 
of Wig-1 leads to differentiation of neuroblastoma cells carrying amplified N-Myc42.  
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1.2 AIMS OF THIS THESIS 
 
The overall aims were to identify Wig-1 mRNA targets and investigate the biological 
implications of the regulation of selected targets. We also wished to evaluate Wig-1 
protein expression in tumors and its correlation to patient survival, and determine the role 
of Wig-1 in mouse development.  
 
Paper I:  To study the effects of Wig-1 knockdown on global gene expression and cell 
survival. To explore the mechanisms of Wig-1-mediated regulation of the pro-apoptotic 
FAS at the mRNA level. 
 
Paper II: To investigate Wig-1 protein expression in cervical carcinoma and study a 
possible association between Wig-1 expression and patient survival.  
 
Paper III: To understand the role of Wig-1 in mouse development and why complete lack 
of Wig-1 causes embryonic lethality.   
 
Paper IV: To characterize the mRNA-binding properties of Wig-1 and identify RNA 
secondary structures involved in Wig-1 mRNA binding on a transcriptome-wide scale.  
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1.3 RESULTS AND DISCUSSION 
Paper I 
Wig-1 regulates cell cycle arrest and cell death through the p53 targets FAS and 14-
3-3σ 
 
Previously, Wig-1 has been shown to bind to and regulate p53109 , N-Myc42 and p21 
mRNAs207. In this study, our goal was to find out other novel Wig-1 target mRNAs.  
 
We first applied microarray analysis to identify Wig-1 target mRNAs by knocking down 
Wig-1 in HCT116 colon cancer cells. Wedentified 2447 transcripts with >4-fold changes 
of expression levels between Wig-1 and control siRNA-treated cells. Using the 
PANTHER software, we analyzed significantly deregulated pathways after Wig-1 
knockdown with Alzheimer’s and Huntington’s diseases, the p53 pathway, the FAS 
signaling pathway and apoptosis among the top ranked pathways.  
 
Eight targets (FAS, WNT1, FZD8, AKT3, APP, 14-3-3σ, CDC42, PPP2CB) were selected 
for validation based on the extent of expression changes after Wig-1 knockdown (KD). 
Changes in protein levels for FAS, WNT1, AKT3, APP, 14-3-3σ, and PPP2CB were 
consistent with the microarray data.  
 
We moved on to study how Wig-1 regulates the targets FAS and 14-3-3σ since: 1) both 
of them are p53 targets and 2) the p53 pathway is one of the most affected pathways after 
Wig-1 KD. We found that Wig-1 binds to and destabilizes FAS mRNA through its ARE 
in the 3'UTR. 14-3-3σ, which does not have any AREs is regulated by Wig-1 positively 
at the level of transcription. We also found that this regulation is p53- independent since 
Wig-1 regulates FAS and 14-3-3σ in both p53 wild type and p53 null HCT116 cells.  
 
As FAS is a proapoptotic factor and 14-3-3σ is involved in cell cycle arrest, we then 
examined if Wig-1 plays a role in controlling the outcomes of cellular stress. We 
observed that Wig-1 KD leads to increased cell death and reduced cell cycle arrest upon 
cellular stress (cisplatin and gamma radiation). In addition to cancer cells, we also 
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examined Wig-1 knockdown in primary human fibroblasts (HDFs) with or without 
gamma irradiation. Our data demonstrate that Wig-1 promotes cell cycle arrest and 
therefore leads to long-term cell survival upon gamma radiation.  
 
How does Wig-1 regulate FAS mRNA stability? Is the ARE-mediated mRNA decay 
pathway involved? Indeed, we found that Wig-1 colocalizes and interacts with CNOT6, a 
component of CCR4–NOT, suggesting that Wig-1 might be the connecting factor 
between FAS mRNA and the deadenylase machinery. Furthermore, immunofluorescence 
and RNA-FISH revealed that Wig-1, CNOT6 and FAS mRNA all localize in stress 
granules after arsenite stress.   
 
To sum up, our results suggest that, in response to cellular stress, Wig-1 acts as a survival 
factor promoting cell cycle arrest rather than cell death through the regulation of FAS and 
14-3-3α mRNA. We also suggest a mechanism through which Wig-1 can destabilize its 
target mRNAs acting as a bridge between the deadenylase complex and its mRNA targets 
in stress granules (Figure 6). This prosurvival function of Wig-1 is also supported by 
paper II and paper III.  
 
 
Figure 6: The proposed regulatory model of FAS by Wig-1. (Bersani et al.,Oncogene, 2014) 
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Paper II 
Expression of the p53 target Wig-1 is associated with HPV status and patient 
survival in cervical carcinoma   
 
Paper I revealed that the p53 target Wig-1 has a prosurvival function. As discussed in the 
introduction, the WIG-1 gene is localized to chromosome 3q26, a region that is amplified 
in many cancer types. Additionally, as revealed by the cancer genomic data, the WIG-1 
gene is amplified in many tumors, including half of lung squamous cell carcinomas, and 
around 20% of ovarian cancer, breast cancer and cervical carcinomas 
(www.cbioportal.org). These results promoted us to study the clinical relevance of Wig-1. 
Therefore, we examined Wig-1 expression in patient samples for the first time and 
explored a possible prognostic value of Wig-1. 
 
We initially examined structural and copy number alterations of the WIG-1 locus in eight 
cervical carcinoma cell lines (Ca Ski, C-4I, C-33A, SiHa, SW756, MS751, ME-180, and 
HT-3) by spectral karyotype and comparative genomic hybridization, respectively. We 
found amplifications in Ca Ski, ME-180 and SiHa cells that involved 3q23–26, 3q27-ter 
and 3q23–24, respectively. We then studied possible alterations of WIG-1 in these cells 
by Southern blotting analysis. This showed modest gains of WIG-1 in MS751 and ME-
180 cells, but not in the other cells. We concluded that 3q amplifications occur in cervical 
cancer cells, but the amplifications are not driven by Wig-1. Additionally, Northern 
blotting and qRT-PCR demonstrated that Wig-1 mRNA levels were higher in the HPV-
negative cervical cancer cell lines than in the HPV-positive lines. However, we found no 
association between Wig-1 protein expression and HPV infection.  
 
We then assessed Wig-1 expression by immunohistochemistry (IHC) in a series of 38 
cervical tumor samples comprising both adenocarcinomas and squamous carcinomas in 
collaboration with Prof. Sonia Andersson at the Dept. of Women's and Children's Health, 
Astrid Lindgren Hospital. We observed higher nuclear Wig-1 expression levels in HPV-
negative cases compared to HPV positive cases (p=0.002), suggesting that elevated Wig-
1 expression might contribute to cervical carcinogenesis in the absence of HPV infection. 
This is consistent with the finding that HPV-negative cervical cancer cell lines have 
higher Wig-1 mRNA expression levels compared to the HPV-negative lines.  
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We also noted that Wg-1 expression levels are significantly higher in adenocarcinomas as 
compared to squamous cell carcinomas (p<0.0001). Most remarkably, we observed 
several distinct Wig-1 staining patterns in cervical tumors and found that patients with 
moderate nuclear Wig-1 staining and positive cytoplasmic Wig-1 staining in their tumors 
had longer survival than patients with strong nuclear and negative cytoplasmic staining 
(p=0.042) (Figure 7).  
 
Log Rank P = 0.042
 n = 8
 n = 13
Moderate nuclear and posi-
tive cytoplasmic Wig-1 stain-
High nuclear and negative 
cytoplasmic Wig-1 staining 
C
 
Figure 7: A. Kaplan-Meier survival curve showing that patients with moderate nuclear and 
positive cytoplasmic Wig-1 staining have better survival than patients with strong nuclear and 
negative cytoplasmic staining (p < 0.05 is considerate to be significant). (Xu et al., PLoS ONE, 
2014) 
 
What is the biological significance of this association? Our previous findings indicate that 
Wig-1 exerts a growth-promoting and/or anti-cell death function by upregulating putative 
targets such as N-Myc and downregulating the pro-apoptotic FAS26,74 (Paper I). 
Therefore, it is conceivable that high nuclear Wig-1 expression in cervical cancer cells 
drives cell proliferation through stabilization of pro-growth mRNA targets while 
destabilizing of the pro-apoptotic mRNA targets. However, the exact roles of nuclear and 
cytoplasmic Wig-1 need to be studied further. 
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To conclude, our finding that Wig-1 expression elevated in HPV-negative cervical 
carcinoma compared to HPV-positive samples suggests a possible role of Wig-1 in HPV-
negative cervical carcinogenesis. Moreover, our data demonstrate that moderate nuclear 
Wig-1 expression levels and positive cytoplasmic Wig-1 staining are associated with 
better prognosis, suggesting that Wig-1 protein expression levels assessed with IHC 
could serve as a novel molecular marker or a molecular marker combined with other 
traditional clinical markers for prognosis of cervical cancers. Our results may contribute 
to a better understanding of the molecular basis of carcinogenesis.  
 
Paper III 
Complete lack of Wig-1 leads to embryonic lethality before the blastocyst stage 
 
The involvement of Wig-1 in proliferation, senescence and differentiation has naturally 
raised the question whether Wig-1 is important for embryonic development. To address 
this, we set out to investigate the role of Wig-1 during mouse embryogenesis.  
 
First, we studied Wig-1 expression in mouse embryos. We found that Wig-1 mRNA is 
expressed at high levels at E5.5 as shown by Northern blotting. Levels then drop 
somewhat to peak again at E10.5-13.5. The expression then decreases markedly. We also 
noticed that Wig-1 protein expression levels are higher in mouse embryonic stem cells 
(mESC) compared to differentiated ESCs. Furthermore, Wig-1 expression is independent 
of p53, at least at E10.5 and E13.5, as indicated from IHC of Wig-1 in p53 knockout 
embryos.   
 
We then generated mice carrying inactivated Wig-1 alleles by targeted deletion of parts 
of exon 2 to exon 4. Intercrossing of heterozygous Wig-1 mice with wild type mice, 
revealed a reduced frequency of heterozygous offspring (12% instead of the expected 
50%) but no other obvious phenotypic abnormalities. Furthermore, we failed to detect 
any Wig-1 null offspring after intercrossing heterozygous mice with each other, 
indicating that complete lack of Wig-1 is associated with embryonic lethality. To find out 
if the Wig-1 null embryos were present at blastocyst stage, we performed in vitro 
fertilization (IVF) and cultured zygotes until the blastocyst stage. Still, we were not able 
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to detect any Wig-1 null blastocysts, suggesting that Wig-1 null embryos die before the 
blastocyst stage.    
 
Next, we asked why complete lack of Wig-1 leads to embryonic lethality. We examined 
cellular processes that might be affected by Wig-1 KD in mESCs. We found that Wig-1 
KD causes a significant reduction in cell proliferation as demonstrated by cell count and 
WST-1 assays, a colorimetric assay for quantification of cellular proliferation and 
viability. Reduced proliferation in the absence of Wig-1 could lead to impaired 
embryonic development, especially in the early pre-implantation embryo. 
 
Since we have shown that Wig-1 is an ARE-BP, we speculated that the early lethality of 
Wig-1 null embryos could be due to deregulation of Wig-1 targeted mRNAs. We have 
already found that Wig-1 regulates N-Myc mRNA via AREs and that Wig-1 KD leads to 
decreased N-Myc mRNA and N-Myc protein levels42. Both c-Myc and N-Myc seem to 
be required for early embryonic development209,210 and maintenance of stem cell survival 
and self-renewal202. Therefore, we hypothesized that the lethality of Wig-1 embryos 
could be due to altered expression of c-Myc and N-Myc.  
 
To test this hypothesis, we examined Wig-1 in mESCs. Wig-1 siRNA KD caused 
attenuated c-Myc and N-Myc protein expression did not affect mRNA levels, suggesting 
that Wig-1 regulates Myc at the translational level. Moreover, we found that Wig-1 binds 
both c-Myc and N-Myc mRNA. These results indicate that the embryonic lethality in the 
absence of Wig-1 is at least in part due to insufficient Myc expression prior to the 
blastocyst stage.  
 
Given that Wig-1 binds to as many as 286 mRNAs (paper IV) and regulates 2447 targets 
either directly or indirectly (paper I), it is likely that Wig-1 knockout affects a number of 
targets that contribute to the embryonic lethality. However, the combined effect of 
reduced expression of c-Myc and N-Myc – two key regulators of cell survival and 
proliferation – by Wig-1 may contribute in a significant way to the phenotype observed 
in Wig-1 knockout mice independently of effects on other targets. Nonetheless, it is 
likely that other Wig-1 targets are also important for the early embryonic lethality. 
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In summary, Wig-1 is expressed in the brain, spinal cord, and fetal liver in C57Bl/6 
embryos in a p53-independent manner. Loss of Wig-1 leads to embryonic lethal, most 
probably due to dysregulation of the Wig-1 targets N-Myc and c-Myc during early 
embryonic development. A model for Wig-1 regulation of Myc during early embryonic 
development is shown in Figure 8.    
 
 
 
Figure 8. Model for Wig-1 regulation of Myc during embryonic development. AREs in the 
3’UTR of Myc mRNA regulate its translation. Wig-1 binds the Myc AREs and recruits ribosomes 
to initiate translation of Myc mRNA. Myc protein can then transactive its target genes and 
promote cell growth that required for normal embryonic development. However, if Wig-1 
expression is shut down, Myc mRNA translation will be abolished or attenuated, resulting in 
impaired Myc expression and embryonic lethality.  
  
42 
Paper IV 
 
Genome-wide identification of Wig-1 mRNA targets by RIP-Seq analysis 
 
The aim of this study was to identify novel Wig-1-associated mRNAs. We performed 
RNA-immunoprecipitation followed by high-throughput sequencing (RIP-Seq) in both 
HCT116 and Saos-2 cells, which resulted in a list of 286 Wig-1-bound mRNAs common 
between both cell lines. By putting all the Wig-1 bound mRNAs into network enrichment 
analysis (NEA), we showed that Wig-1 targets are highly connected with the Cell Cycle 
pathways, in accordance with paper I.  
 
For validation, we selected nine Wig-1-associated mRNAs out of the 286 mRNA that are 
enriched in both HCT116 and Saos2 cells: MAD2L1, MTHFD2, CCNG1, EIF4E, 
CHEK1, RMI1, HIF1A, AMD1 and CAV1. By RNA-IP followed with qRT-PCR, we 
validated all nine targets in HCT116 and 6 of the targets in Saos2 cells. Additionally, we 
found that Wig-1 knockdown in HCT116 cells decreased the expression levels of 
MTHFD2, EIF4E, RMI1 and CAV1 mRNA but led to an increased level of HIF1A 
mRNA. These findings demonstrate that Wig-1 can both stabilize and destabilize its 
RNA targets, including pro-and anti-proliferation factors. 
 
We further examined the features of Wig-1-bound mRNAs. Sequence analysis revealed 
that AREs and/or generally AU-rich motifs are highly enriched in the 3'UTR of these 
mRNAs. Secondary structure analysis identified a shared consensus 2D motif among the 
nine validated targets. 
 
To summarize, our findings in this study are consistent with our previous data on Wig-1 
as an ARE-BP that regulates cell cycle and cell death-related processes. In addition, the 
present study provides a more comprehensive picture of preferred Wig-1 binding motifs 
and significantly extends the repertoire of Wig-1 target mRNAs. 
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1.4 CONCLUSION AND FINAL DIRECTIONS  
Coming back to our first question in the Introduction: What is Wig-1? What is the 
cellular function(s) of Wig-1? I hope I have managed to tell you a good story of Wig-1 
and inspired you to develop some interest in Wig-1 now. Compared to p53 which has 
more than 77, 000 publications indexed to PubMed from 1979, Wig-1 has so far only 
around 50 publications in total since its discovery in 1997, leaving us much to do in the 
field of research on Wig-1.  
 
Wig-1 is one of the p53 targets, whose RNA and protein expression levels increase after 
p53 activation. Both human and mouse Wig-1 have p53 response elements.   
 
Wig-1 is an AU-rich element-binding protein (ARE-BP) that regulates its target mRNAs 
at the post-transcriptional level via direct binding to AREs. Through paper I and paper IV 
in this thesis, we have extended the list of published Wig-1 targets from p53, N-Myc and 
p21 to FAS and 14-3-3σ, both downstream targets of p53, and possibly other genes with 
relevance for cancer, like MTHFD2, RMI1, CAV1 and EIF4E. Interestingly, EIF4E, the 
eukaryotic translation initiation factor 4E, is a key player in translational control211,212 by 
recognizing 5’cap of mRNAs. EIF4E has been shown to be bound and stabilized by HuR 
via an ARE in the 3’UTR213. In paper IV, we showed Wig-1 binds to and stabilizes 
EIF4E mRNA, which may contribute to EIF4E mediated translation. If further study can 
show that Wig-1 knockdown affect N-Myc translation via downregulating EIF4E, this 
will support our proposed model for Wig-1 regulation of Myc at the translational level 
during embryogenesis, as shown in paper III (Figure 8).  
 
Although we have shown that Wig-1 can regulate mRNAs by affecting their stability42,109 
(paper I) or possibly translation (paper III), we are still open to other possible functions of 
Wig-1 at various levels of gene regulation, such as alternative splicing and mRNA export 
from nucleus to cytoplasm, as for other ARE-BPs. We also believe that Wig-1 affects cell 
growth more than by just preventing apoptosis or senescence110. Indeed, data from our 
lab suggest that Wig-1 can affect the cellular redox system (S. Eriksson, unpublished 
results).  
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Moreover, we have also noted that Wig-1 binds and destabilizes HIF1A mRNA (paper 
IV). Previous studies have shown that p53 negatively regulates both HIF1A transcription 
and protein levels214. Our data suggest that p53 regulates HIF1A through Wig-1. As 
discussed in the Introduction, p53-mediated cell cycle arrest, apoptosis and senescence do 
not appear to be crucial for p53-mediated tumor suppression36,37. Li et al., have shown 
that p53 inhibits cysteine uptake and sensitizes cells to ROS-induced cell death 215. 
Therefore, It would be interesting to examine if Wig-1 pays also a role in the regulation 
of hypoxia-induced p53-dependent apoptosis or metabolic regulation.  
 
Paper II concludes that Wig-1 expression patterns in tumor samples are associated with 
prognosis. Patients with moderate nuclear Wig-1 expression and positive cytoplasmic 
Wig-1 expression in their tumors have better survival compared to patients with high 
nuclear Wig-1 expression and negative cytoplasmic Wig-1 expression. This finding 
implies that the Wig-1 protein might serve as a molecular marker together with other 
conventional clinical markers for prognosis of cervical cancer. Indeed, Wig-1 expression 
is associated with chemosensitivity, overall survival and clinical stage in small cell lung 
cancer (SCLC). Wig-1 silencing reduced SCLC resistance to several drugs including 
cisplatin, doxorubicin and etoposide by increasing apoptosis216. Moreover, Wig-1 
knockdown was shown to sensitize human lymphoblastoid cells (LCLs) and non-small 
cell lung cancer cells (A549) to pemetrexed treatment217. From a therapeutic point of 
view, we believe that further studies need to be carried out to investigate the clinical 
significance of Wig-1 expression. We also believe that full understanding of how Wig-1 
regulates its target mRNAs will serve to develop potential diagnostic and therapeutic 
strategies against cancer. 
 
Paper III shows that Wig-1 null embryos die before the blastocyst stage. Intercrossing of 
Wig-1 heterozygous (wig-1+/-) mice with Wig-1 wt (Wig-1+/+) mice revealed a skewed 
ratio between Wig-1 +/+ and Wig-1 +/- offsprings (88%:12%), which is significantly 
different from the expected Mendelian ratio (50%:50%). No other obvious phenotypic 
abnormalities are evident. These findings indicate that Wig-1 is essential for early 
embryonic development. Since no Wig-1 null mice are born, studies of the effect of 
complete lack of Wig-1 in adult tissues must be carried out using conditional knock out 
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systems. We are currently in the process of generating such mice. They can be used to 
investigate tumor formation in tissues lacking Wig-1 (e.g. lung or cervix) and hopefully 
provide information about the exact roles of Wig-1 in tumor development. We should 
also achieve a better understanding of the physiological functions of Wig-1 in specific 
tissues.  
 
Altogether, we believe that Wig-1 is a pro-survival factor and a critical regulator of 
embryonic development. In addition, Wig-1 may be of great significance in cancer 
development and therapy resistance.  
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的关爱是永恒而深远的，希望你在天堂安详。 
 
致我亲爱的夫君芃，芃的爸爸妈妈和爷爷奶奶 
徐妈妈和张爸爸，感谢你们生养了芃，也感谢你们像对待女儿一样关心爱护我。
爷爷奶奶你们放心，我们会互爱，互敬，互勉，互慰，互让，互谅，互助，互
学。 
 
芃，跟你在一起的日子特别开心，特别自在。据说最好的伴侣是可以激发内心中
最好的自己，我觉得你比认识我以前更好了呢，啊，当然，我也是。你了解我时
常的不理智和冲动，宽慰我实验挫败后的郁闷心情，接受我的坏脾气和习惯性迟
到。你总是一如既往地支持我，陪伴我，你的宽容你的逗比你的精湛厨艺统统都
是我的药。 
 
我们可爱的小麦麦，真等不及要见到你，爸爸和妈妈都很爱你！  
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